Publication: Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat
dc.contributor.author | J. Tarning | en_US |
dc.contributor.author | N. Lindegardh | en_US |
dc.contributor.author | S. Sandberg | en_US |
dc.contributor.author | N. J.P. Day | en_US |
dc.contributor.author | N. J. White | en_US |
dc.contributor.author | M. Ashton | en_US |
dc.contributor.other | Goteborg University, Sahlgrenska Academy | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Churchill Hospital | en_US |
dc.date.accessioned | 2018-07-12T02:51:55Z | |
dc.date.available | 2018-07-12T02:51:55Z | |
dc.date.issued | 2008-01-01 | en_US |
dc.description.abstract | This study aimed to evaluate the pharmacokinetic properties of pipera-quine in the rat after intravenous and oral administration, and to identify and characterize the main piperaquine metabolites in rat plasma, urine, faeces and bile after intravenous administration. Male Sprague - Dawley rats were administered piperaquine as an emulsion orally or as a short-term intravenous infusion. Venous blood for pharmacokinetic evaluation was frequently withdrawn up to 90 h after dose. Urine, bile and faeces were collected after an infusion in rats kept in metabolic cages or in anesthetized rats. Pharmacokinetic characterization was done by compartmental modeling and non-compartmental analysis using WinNonlin. Piperaquine disposition was best described by a 3-compartment model with a rapid initial distribution phase after intravenous administration. The pharmacokinetics of piperaquine was characterized by a low clearance, a large volume of distribution and a long terminal half-life. Piperaquine displayed a low biliary clearance and less than 1% of the total dose was recovered in urine. The absolute oral bioavailability was approximately 50%. The main metabolite after intravenous administration of piperaquine was a carboxylic acid product identical to that reported in humans. The similarity with results in humans indicates the rat to be a suitable species for nonclinical in vivo piperaquine studies. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association. | en_US |
dc.identifier.citation | Journal of Pharmaceutical Sciences. Vol.97, No.8 (2008), 3400-3410 | en_US |
dc.identifier.doi | 10.1002/jps.21226 | en_US |
dc.identifier.issn | 15206017 | en_US |
dc.identifier.issn | 00223549 | en_US |
dc.identifier.other | 2-s2.0-52449086887 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/19884 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=52449086887&origin=inward | en_US |
dc.subject | Pharmacology, Toxicology and Pharmaceutics | en_US |
dc.title | Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=52449086887&origin=inward | en_US |